NCT00645918

GRAVITAS: Gauging Responsiveness With A VerifyNow Assay-Impact On Thrombosis And Safety

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 2,800 (actual)
• Sponsor: Accumetrics, Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The objective of the GRAVITAS trial is to determine whether tailored anti-platelet therapy using the Accumetrics VerifyNow P2Y12 assay reduces major adverse cardiovascular events after drug-eluting stent implantation.

Conditions

• Coronary Arteriosclerosis
• Acute Coronary Syndrome

Interventions

Type	Name	Description
DRUG	clopidogrel	oral, 75 mg daily for 6 months starting on day of randomization
DRUG	placebo	oral, 6 pill loading dose on day of randomization; one pill daily for 6 months starting on day of randomization
DRUG	clopidogrel	oral, 450 mg loading dose on day of randomization; 75 mg daily for 6 months starting on day of randomization

Timeline

• Start date: 2008-06-01
• Primary completion: 2010-10-01
• Completion: 2010-10-01
• First posted: 2008-03-28
• Last updated: 2011-06-16

Locations

82 sites across 2 countries: United States, Canada